NIP
IOVA icon

Nicholas Investment Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Nicholas Investment Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-507,651
Closed -$23.6M – 199
2020
Q4 		$23.6M Buy
507,651
+837
+0.2% +$33.2K 1.82% 7
2020
Q3 		$16.7M Buy
506,814
+422,298
+500% +$12.9M 1.8% 10
2020
Q2 		$2.32M Sell
84,516
-97,473
-54% -$3.2M 0.47% 84
2020
Q1 		$5.45M Buy
181,989
+42,411
+30% +$1.12M 1.06% 23
2019
Q4 		$3.86M Buy
+139,578
New +$3.17M 0.4% 86

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nicholas Investment Partners's IOVA Position: Q1 2021 in Review

Nicholas Investment Partners sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 507,651 shares — an estimated $23.6M sold.

Nicholas Investment Partners first reported a position in IOVA in Q4 2019 and held it in 5 quarters. The position peaked at $23.6M in Q4 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

  • Nicholas Investment Partners reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Nicholas Investment Partners sold 507,651 Iovance Biotherapeutics shares in Q1 2021, an estimated $23.6M.
  • Nicholas Investment Partners first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 5 quarters.
  • Nicholas Investment Partners's Iovance Biotherapeutics position peaked at $23.6M in Q4 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on Nicholas Investment Partners's 13F filing for Q1 2021, filed 14 May 2021.